NephroPlus Q1FY27 Results: Revenue up 23.7% to ₹281.8 Cr, PAT grows 41.7%
NephroPlus reported Q1FY27 revenue of ₹281.8 crore, up 23.7% YoY, with treatments up 13.3% and guests up 13.0%. Adjusted EBITDA grew 30.7% YoY to ₹65.1 crore, and Adjusted PAT increased 41.7% YoY to ₹36.8 crore. The company expanded its network to 550 clinics globally.
The announcement details significant financial growth (revenue, EBITDA, PAT) and strategic expansion, which are material factors for investors and stakeholders.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with an expansion of its network and introduction of new initiatives, indicating positive financial and operational performance.
Nephrocare Health Services Limited (NephroPlus) announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported a revenue from operations of ₹281.8 crore, marking a significant year-on-year increase of 23.7%. This growth was driven by a 13.3% YoY increase in treatments to 10.31 lakh and a 13.0% YoY rise in guests to 38,262. Additionally, the revenue per treatment saw a 9.2% YoY improvement, reaching ₹2,733.
Adjusted EBITDA for the quarter stood at ₹65.1 crore, up 30.7% YoY, with the adjusted EBITDA margin expanding by 120 basis points to 23.1%. Adjusted Profit After Tax (PAT) demonstrated robust growth, increasing by 41.7% YoY to ₹36.8 crore. The company highlighted its expanding network, which reached 550 operating clinics across five countries, including a milestone of 50 clinics in the Philippines.
NephroPlus also launched the NephroPlus International Dialysis Academy (NIDA) to train renal nurses for its international operations. Initiatives to increase fistula creation and reduce cross-infections were also undertaken, alongside the launch of the NephroPlus Dialysis Index to monitor clinical outcomes. The management expressed confidence in profitable and efficient growth while delivering superior clinical quality across all markets.
What to do with a filing like this
Nephrocare Health Services Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nephrocare Health Services Limited. Read the original for the full detail.